跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
QUVIVIQ - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
QUVIVIQ
Authorized
STANDARD
QUVIVIQ
Idorsia Pharmaceuticals Ltd
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
0df74f641b61fc85
Company
Idorsia Pharmaceuticals Ltd
Type
Standard
Approval Details
Approval Id
0df74f641b61fc85
Drug Approval Canada Name
QUVIVIQ
Product Name
QUVIVIQ
Status
Marketed
Status Date
2023-07-12
Original Market Date
2023-07-12
Din
02537443
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
28:24.40
Atc Original
N05CJ03 DARIDOREXANT
Atc Name
n 05 cj 03
Aig Number
0164601002
Company Name
Idorsia Pharmaceuticals Ltd
Company Address
Hegenheimermattweg 91, Allschwil, Basel-Landschaft, Switzerland, 4123
Company Detail Path
/organization/idorsia-pharmaceuticals-ltd
Company Information
Pharmaceutical Company Name
Idorsia Pharmaceuticals Ltd
Country Name
Switzerland
Province Name
Basel-Land
City Name
allschwil,basel-land,country_ch
Address
Hegenheimermattweg 91
Active Ingredients
DARIDOREXANT (DARIDOREXANT HYDROCHLORIDE)
50 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
0df74f641b61fc85
Type
Standard
Back to Health Canada Approvals